Business Context and Reporting Period
This Form 8-K Current Report was filed by Anika Therapeutics, Inc. on January 7, 2026, covering events reported on January 7 and January 8, 2026. The filing addresses the reaffirmation of financial guidance for the fiscal year ending December 31, 2025, and significant changes in executive leadership and board composition effective February 1, 2026.
Key Financial Metrics and Guidance
The Company reaffirmed its 2025 revenue and profitability guidance as follows:
- Commercial Channel Revenue: $47 million to $49.5 million (up 12% to 18% year over year).
- OEM Channel Revenue: $62 million to $65 million (down 16% to 20% year over year).
- Adjusted EBITDA Margin: Expected to range from positive 3% to negative 3% of revenue.
The filing does not provide specific historical revenue, profit, cash flow, debt, or liquidity figures for the current or prior periods; it focuses solely on forward-looking guidance.
Material Changes and Management Commentary
Executive Leadership Transition
Effective February 1, 2026, Cheryl R. Blanchard will transition from President and Chief Executive Officer (CEO) to Executive Chair of the Board for 12 months, followed by a 6-month term as Special Advisor, and finally a 6-month period as an employee before her anticipated separation on January 31, 2028. She will remain a director through the 2028 Annual Meeting.
Steve Griffin, currently Executive Vice President, CFO, and COO, has been appointed President and CEO effective February 1, 2026. He will also serve as the principal financial officer.
Board Changes
Susan N. Vogt resigned from the Board and all committees effective February 1, 2026. Steve Griffin was appointed to the Board effective February 1, 2026, serving as a Class III director until the 2026 annual meeting.
Compensation Arrangements
- Dr. Blanchard: Entitled to 18 months of base salary paid over 24 months, continued health benefits, and vesting of existing equity awards. Eligible for a 2025 cash incentive bonus at the Board's discretion.
- Mr. Griffin: Annual base salary of $690,000 with a target annual bonus of 75% of base salary starting in fiscal 2026. Granted equity awards with a target fair value of $2,450,000 (50% RSUs, 50% SARs) vesting over three years.
Risks and Contingencies
The filing notes that the financial guidance and press release information are not deemed "filed" under Section 18 of the Exchange Act and are not subject to incorporation by reference. The transition of leadership and the resignation of a director are disclosed as material events, though no specific disagreements regarding operations or policies were noted regarding the departing director.
Investor Verification Checklist
- Verify the specific terms of the Transitional Services and Separation Agreement (Exhibit 10.1) regarding Dr. Blanchard's compensation and separation timeline.
- Review the Employment Agreement (Exhibit 10.2) for Mr. Griffin to confirm vesting schedules and performance conditions for the $2.45 million equity grant.
- Monitor the Company's ability to meet the narrowed Adjusted EBITDA margin guidance (positive 3% to negative 3%) given the divergence between growing Commercial revenue and declining OEM revenue.
- Confirm the status of the 2025 cash incentive bonus determination for Dr. Blanchard, which remains at the Board's sole discretion.